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Abstract: The aim of this study was to develop novel biomedicated nanofiber electrospun 
mats for controlled drug release, especially drug release directly to an injury site to accelerate 
wound healing. Nanofibers of poly(vinyl alcohol) (PVA), poly(vinyl acetate) (PVAc), and a 
50:50 composite blend, loaded with ciprofloxacin HCl (CipHCl), were successfully prepared 
by an electrospinning technique for the first time. The morphology and average diameter of the 
electrospun nanofibers were investigated by scanning electron microscopy. X-ray diffraction 
studies indicated an amorphous distribution of the drug inside the nanofiber blend. Introducing 
the drug into polymeric solutions significantly decreased solution viscosities as well as nano-
fiber diameter. In vitro drug release evaluations showed that both the kind of polymer and the 
amount of drug loaded greatly affected the degree of swelling, weight loss, and initial burst 
and rate of drug release. Blending PVA and PVAc exhibited a useful and convenient method 
for electrospinning in order to control the rate and period of drug release in wound healing 
applications. Also, the thickness of the blend nanofiber mats strongly influenced the initial 
release and rate of drug release.
Keywords: biodegradable polymers, drug delivery, controlled release, electrospun nanofibers, 
wound dressing
Introduction
A wound dressing should ideally provide an optimal healing environment in which 
healing can occur at a maximum rate compatible with the cosmetic appearance of the 
healed wound;1,2 however, the infection under dressing caused by burns, split skin 
graft donor sites, pressure, sores, and diabetic ulcers can lead to prolonged healing 
time or, in serious conditions, death. Consequently, wounds often require treatment 
with antibiotics.2–5 Local delivery of drugs sustained for about 1 week is preferred to 
systemic administration, especially for chronic wounds,5 because of the advantages 
of these delivery systems such as: a) improving the effectiveness of drug therapy, and 
selective targeting, b) decreasing the side effects on a tissue, and interference with 
wound healing, c) reduction of bacterial resistance, and d) reducing the frequency of 
dressing replacements to increase patient compliance.4,5 Furthermore, a proper wound 
dressing needs to have wound healing properties, including the essential swelling 
capability for absorbing excess exudates and oxygen permeability for respiring.5,6 
Modern dressings as vehicles for delivering therapeutic agents to wound sites have 
been applied in the form of hydrogels,2 films,7 sponges,8 foams,9 and recently in the 
form of nanofibers.6,10 However, little research has been published on the controlled 
delivery of drugs from polymeric dressing, especially in the form of nanofibers.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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In the last decade, nanofibers have attracted increasing 
attention for their use in biomedical applications such as 
wound dressings,10–12 tissue engineering,11 and controlled 
drug delivery.13–21 The very fine diameter and high porous 
structure of nanofiber mats help drug particles diffuse out of 
the matrix more efficiently.14,15
The most popular, preferred, and inexpensive technique 
for fabricating polymeric nanofibers is electrospinning. 
Unlike common techniques, electrospinning is more con-
venient for incorporating therapeutic compounds into the 
polymeric matrix.11 Using electrospun nanofiber mats for 
wound dressings also has some benefits, such as hemostatic 
properties, absorbability and semipermeability for respiration 
of cells, better conformation to the wound surface,11 and the 
potential for leaving no scar.11,12
Among wound dressings, special attention has been paid 
to biodegradable polymeric dressings because they can   easily 
be washed off the wound surface.4,5 Poly(vinyl alcohol) 
(PVA) is a well-known, biologically friendly, biodegradable 
polymer owing to its desirable properties such as nontoxic-
ity, no carcinogenicity, biocompatibility, and appropriate 
mechanical properties.1,2,7,18 Because of these properties, 
PVA is used in some biomedical applications such as soft 
contact lenses, implants of artificial organs, cartilage skin, 
and cardiovascular devices.2,18 Because of its flexibility 
and swelling capability in an aqueous medium, PVA has 
been much studied as a wound dressing;2 however, its poor 
stability in water has limited its use in aqueous systems, 
particularly for drug-delivery applications.18,22 To overcome 
this problem, PVA has been made insoluble by grafting,18 
copolymerizing,22 and cross-linking,23 which require some 
additional and sometimes complicated and time-consuming 
processes. In wound dressing applications, PVA has been 
crosslinked with polyvinyl pyrrolidone,2 sodium alginate,24 
and sterculia25 to provide better characteristics, although a 
vey quick release burst was reported and a sustained release 
continued up to 90 hours, 5 hours, and 24 hours, respectively. 
Poly(vinyl acetate) (PVAc), a biocompatible and biodegrad-
able (owing to the hydrolyzable groups in the side chain) 
polymer, has also been used in biomedical applications, 
including drug and cell carriers, and tissue engineering.26,27
PVA is a well-known biocompatible and nontoxic 
  polymer. Biocompatibility of PVA is due to both its com-
patibility with tissue and blood (plasma proteins), which 
has been widely reported. For this reason, PVA has been 
used in numerous devices in contact with blood and tissues 
such as drug-delivery systems, wound dressings, dialysis 
  membranes,   cardiovascular devices, artificial cartilage,   tendon, 
  ligament, cornea, lens, skin, and intervertebral disc.4,23,28 
A good   blood-contact property was observed for pure PVA.29 
Moreover, bovine serum albumin (BSA) tends to adsorb to 
hydrophobic surfaces more than hydrophilic ones.30 PVA has 
good blood   compatibility.24 Ex vivo experiments with canine 
whole blood have shown that formation of thrombus on PVA 
is less than on siliconized glass.31 Methods such as blending, 
grafting, and copolymerization of PVA with other polymers 
have improved blood compatibility of those polymers, 
  indicating a very high blood compatibility of PVA.
Several reports have indicated blood compatibility of 
PVAc. PVAc has also been applied in many medical fields 
because of its biocompatibility. Hydrogels such as PVAc 
containing functional groups such as COOH usually show 
good biocompatibility in contact with blood, body fluids, 
and tissues.32 In another study, PVAc did not adsorb sero-
tonin from platelet-free plasma, and did not cause lysis of 
erythrocytes.33 PVAc is an inert polymer with the advantage 
that it does not induce a deleterious reaction in living tissue. 
Histological study of the embolized rat kidney revealed no 
detectable damage in the vessel wall and no recanalization for 
up to 6 months. Also it was shown that PVAc remained inert 
in blood vessels.34 Several patents are registered for novel 
compositions suitable for use in embolizing blood vessels 
using biocompatible polymers including PVAc. The compo-
sition of these inventions are particularly useful in embolizing 
blood vessels35 or they can be applied to intravascular medical 
devices.36 The amount of serum albumin adsorbed onto the 
PVAc latex is considerably low, especially at a pH of 5 to 8, 
indicating its good compatibility with blood.37 There were 
no procedural complications, and no thrombus formation on 
the electrodes of the PVAc catheter.38 Several studies have 
shown that PVAc improves blood compatibility of some 
polymers, thus demonstrating the good blood compatibility 
of this polymer.39
Ciprofloxacin, a fluoroquinolone antibiotic, is one of the 
most widely used antibiotics in wound healing because of its 
low minimal inhibitory concentration for both Gram-positive 
Staphylococcus and Gram-negative Pseudomonas bacteria 
that cause wound infections.2,3
In the present research, an economical and convenient 
method of blending was applied to achieve a simultaneous 
controlled release of CipHCl and high swelling capacity 
along with coverage conformability for wound healing 
  administration. PVAc, as an inexpensive and hydrophobic 
polymer, was selected to be blended with PVA   solution. International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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While PVAc is insoluble in water (a good solvent of PVA),18 
an aqueous solution of 50% acetic acid was used as an 
  appropriate   solvent to dissolve both polymers and also 
CipHCl to attain a stable blend solution. The resulting solu-
tion was electrospun into nanofibers.
Materials and methods
Materials
PVA (MW = 72,000 Da, hydrolysis 98%) and acetic acid were 
purchased from Merck Chemical Co (Darmstadt,   Germany), 
PVAc (MW = 55,000–70,000 Da) was obtained from Carl 
Roth GmbH (Karlsruhe, Germany), and CipHCl was supplied 
from TEMAD Co (Tehran, Iran).
Preparation of pure and drug-loaded 
nanofiber mats
Aqueous acetic acid solution diluted to 50% with distilled 
water was used as the solvent for PVA and PVAc. The 
PVA solutions were prepared by dissolving 5% w/v of PVA 
powder in 50% acetic acid solution at 70°C for 3 hours. 
The obtained solution was stirred for 17 hours at room 
  temperature. To prepare PVAc solutions, 32% w/v of PVAc 
granules was dissolved in 50% acetic acid solution and stirred 
at room temperature for at least 20 hours. PVAc granules 
were added to the cooled solution of PVA and stirred for 
17 hours to prepare the blend solutions of 50:50 by weight 
(8.5% w/v). CipHCl powder (5 or 10% w/w based on the 
polymer used) was added to the polymer solutions 2 hours 
before electrospinning.
The electrospinning solution was transferred to a 1 mL 
syringe pump with a right angle-shaped needle (gauge 22) 
attached to it. The resulting fibers were collected on a 
grounded aluminum plate. All electrospinning processes 
were carried out at 25°C. The solution flow rate was 0.8 to 
1.3 mL/hour, the range of applied positive voltage was 15 
to 19 kV , and the distance between the needle tip and the 
target was 22 cm. The mat thickness was measured using a 
thickness tester (Model No 674, range 0–10.00 mm; Hans 
Baer, Zurich, Switzerland). The thickness of the electrospun 
nanofiber mats ranged from 300 to 360 µm. The electrospun 
nanofiber mats of PVA:PVAc (50:50 by weight) are hereafter 
termed blend nanofiber mats.
characterization of electrospun solutions
Before the electrospinning, the conductivity and viscosity of 
solutions were measured using a conductivity meter (3540; 
Jenway, Germany) and a Brookfield digital   viscometer 
(LVDV-II + PRG, Middleboro, MA), respectively. The 
  average value of three determinations was obtained and 
reported as mean ± SD.
Morphology studies
The morphology of electrospun nanofibers was studied 
by a scanning electron microscope (XL-30, SEM; Philips, 
Amsterdam, the Netherlands) after gold coating. The aver-
age diameter was determined from the SEM images of 
each sample. From each image, at least 100 different fiber 
segments were randomly selected and their diameters were 
measured using Motic software (v 2, Richmond, BC).
X-ray diffraction studies
X-ray diffraction (XRD) was used to investigate the effect 
of electrospinning on the degree of crystallization of the 
drug as well as the influence of the drug on the crystalline 
structure of polymer nanofibers. The XRD patterns of pure 
CipHCl and blend nanofiber mats with and without drug 
were determined using a diffractometer (X pern; Philips, 
Amsterdam, the Netherlands). The scanning range varied 
from 2θ = 5° to 40°.
Degree of swelling and weight loss
The degree of swelling and weight loss of nanofiber mats 
were calculated by Equations 1 and 2, respectively. Both tests 
were carried out in the release medium (phosphate buffered 
saline [PBS], pH 7.4) at 37°C for 1, 4, and 24 hours.
 
Degree of swelling (%) 100   =
−
×
MM
M
d
d
  (1)
 
Weight loss (%) 100 =
−
×
MM
M
id
i
  (2)
where M is the weight of swollen nanofibers sample which is 
wiped dry with filter paper, Md is the dried mass of immersed 
sample in buffer medium, measured by drying the swollen 
nanofiber mats in an oven at 40°C until constant weight was 
reached, and Mi is the initial dry mass of sample.
In vitro drug release studies
Drug release from electrospun nanofiber mats was measured 
by placing a known mass and approximate dimensions 
(2.5 × 2.5 cm) of material into 20 mL of PBS (pH 7.4) under 
constant stirring at 37°C. At certain time points, a nanofiber 
sample was taken out of the buffer and placed into a fresh 
buffer solution. The amount of drug released was determined International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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using a UV spectrophotometer at λmax = 271 nm. The release 
experiments of each sample were performed in triplicate, and 
average values are reported.
Analysis of drug-release kinetics  
and modeling
The release kinetics of drugs from a polymer carrier can be 
described using the Peppas equation:
 M t /M∞ = Ktn  (3)
where Mt is the accumulative amount of drug released 
at time t, M∞ is the initial drug loading, K is a constant 
characteristic of the drug–polymer system, and n is the 
diffusion exponent suggesting the nature of the release 
mechanism.20 In addition to Fickian theory, four more 
models were used to further analyze the profile of drug 
release including zero order, first order, Higuchi, and 
Hixson–Crowell models.40
statistical analysis
Statistical analysis of data was performed using SPSS 
  software package (v 11; SPSS, Inc, Chicago, IL) by one-way 
analysis of variance (ANOVA), assuming a confidence level 
of 95% (P , 0.05) for statistical significance. All data were 
presented as mean ± standard deviation.
Results and discussion
Morphological structure studies
During electrospinning, as the liquid jet (polymeric solu-
tion) is continuously elongated, the solvent of polymeric 
jet is evaporated quickly, phase separation occurs, the jet 
solidifies, and nanofibers are formed. In this process, nanofi-
bers without solvent are deposited on the collector; however, 
to ensure that acetic acid did not remain in the nanofiber 
mats, the mats were dried in a vacuum dryer for 48 hours 
(at room temperature) to remove the solvent. This method 
is also reported in other references41–43 for removing DMF, 
trifluoroacetic acid, and 50% acetic acid from nanofibers. 
For in vivo experiments, however, some methods such as gas 
chromatography may be used to verify if solvent remains 
in the webs after vacuum drying.
As seen in Figure 1, no beaded nanofibers and no drug 
crystals were detected by electron microscopy on the sur-
face or outside the fibers loaded with the drug, showing that 
CipHCl was loaded in the nanofibers, and demonstrating a 
good compatibility of drug–polymers–solvent.19   Furthermore, 
Figures 1G and 1H indicate that loading CipHCl (10% wt) 
into the blend nanofibers (50:50 PVA:PVAc) did not influ-
ence the appearance of the nanofiber mats.
The resulting nanofibers also showed that the incorpora-
tion of the drug into the nanofibers not only dramatically 
decreased their average diameter but also reduced the diam-
eter distribution of electrospun nanofibers from 198, 218, and 
448 nm to 145, 180, and 405 nm for PVA, PVAc, and a blend 
of PVA/PVAc, respectively, as shown in Figures 1 and 2A. 
The measurements of viscosity and conductivity of solutions 
showed that the addition of CipHCl can significantly decrease 
solution viscosity (Figure 2B); however, it did not affect 
solution conductivity (data not shown). Solution viscosity 
influences the morphological structure and average size of 
resulting fibers.13,16,20
Figure 1 (Continued)International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Figure 1 SEM photographs of electrospun nanofibers without drug and with 10% w/w drug loaded: A, B) PVA; C, D) PVAc; E, F) a 50:50 blend of PVA/PVAc; G, H) effect 
of drug loading on appearance of PVA/PVAc blend nanofiber mats.
Abbreviations: CipHCl, ciprofloxacin HCl; PVA, polyvinyl alcohol; PVA/PVAc, polyvinyl acetate.
(Continued)International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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the release medium (PBS, pH 7.4) at 37°C for 1, 4, and 
24 hours. As can be seen, both the degree of swelling and 
weight loss, which are two important factors contributing 
to drug release, were in the order of PVA . the blend of 
PVA:PVAc (50:50) .. PVAc nanofiber mats owing to 
their hydrophilic–hydrophobic properties.
Although the degree of swelling of the blend nanofiber mats 
leveled off in comparison with PVA nanofibers, it was still 
high enough to be used in wound dressings to absorb excess 
exudates even from deep wounds with high amounts of exu-
dates, compared with other results reported.1–3,23–25 The degree 
of swelling is 203%, 231% and 416% after 1 h, 4 h, and 24 h 
submersion of the blend nanofibrous mats, respectively.
As demonstrated in Figure 4C, at the earlier stages, the 
degree of swelling and the thickness of the PVA:PVAc blend 
nanofiber mats are inversely related, ie, the thinner the nano-
fiber mats, the greater the degree of swelling. However, the 
degree of swelling after 24 hours of submersion was greater 
in the thicker nanofibers.
As calculated from the slope of the lines of the changes 
of swelling vs time (Figure 4), the swelling rate for the fibers 
with a thickness of 100 to 140 µm is 7.8% per hour, for 300 
to 360 µm 9.2% per hour, and for 690 to 780 µm 10.9% per 
hour. Nanofiber mats are composed of a great many nanofiber 
layers: the thicker the mat, the more the layers, and therefore 
the more compact the interior layers of nanofibers. Over 
time, the liquid phase has enough time to penetrate into the 
interior layers and reaches a balance. On the other hand, the 
more compact areas in thicker nanofibrous mats result in 
the entrapment of more aqueous molecules in these spaces. 
As a result, the degree of swelling increases with increased 
thickness of nanofibrous mats.
Figure 2 effect of ciphcl on A) the diameter of nanofibers (n = 100) and B) the solution viscosity (n = 3).
Abbreviations: PVA, polyvinyl alcohol; PVA/PVAc, polyvinyl acetate.
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A possible explanation for the decreasing viscosity of the 
polymeric solution by addition of CipHCl is that the drug 
could be trapped between polymeric chains, and thus acts 
as a plasticizer.16
In general, the electrospun polymeric solution with 
higher viscosity causes more resistance to elongation   during 
  electrospinning. In other words, a decrease in solution viscos-
ity causes the spinning jet to be stretched and elongated more 
easily. Consequently, finer fibers can result.13
XrD studies
CipHCl powder, pure electrospun PVA:PVAc nanofibers, 
and 10% w/w drug-loaded PVA:PVAc nanofibers were 
studied by XRD in order to further illustrate the physical 
structure and distribution of the drug in the nanofibers. As 
seen in Figure 3A, CipHCl has several characteristic peaks 
at 2ϑ = 19.04, 24.8, 26.6, and 29.4 because of its regular 
  crystallization.44 XRD pattern of pure PVA:PVAc nano-
fibers seen in Figure 3B shows typical crystalline peaks 
at 2ϑ = 13.9, 16.8, 18.4, 26.3, and 28.3. Blend nanofiber 
mats loaded with 10% w/w CipHCl have the same peaks at 
2ϑ = 13.8, 16.9, 18.3, 26.2, and 28.2 (Figure 3C), proving 
that loading the drug did not change the typical crystallinity 
of the PVA:PVAc blend nanofibers.
Disappearance of the peaks corresponding to the crystal-
line CipHCl in PVA:PVAc nanofibers containing 10% w/w 
drug verified that the drug was dispersed in the polymeric 
nanofiber matrix in the amorphous phase.
Degree of swelling and weight loss
Figures 4A and 4B show the degree of swelling and weight 
loss of PVA, PVAc, and 50:50 blend nanofiber mats in International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Figure  3  X-ray  diffraction  of  A)  ciphcl  powder,  B)  pure  50:50  PVA/PVAc 
nanofiber mat, and C) 50:50 PVA/PVAc nanofiber mat loaded with 10% w/w drug.
Abbreviations:  CipHCl,  ciprofloxacin  HCl;  PVA,  polyvinyl  alcohol;  PVA/PVAc, 
polyvinyl acetate.
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nanofiber mat, and C) effect of the thickness of blend nanofiber mats on the degree 
of swelling (%) (n = 3).
Abbreviations: PVA, polyvinyl alcohol; PVA/PVAc, polyvinyl acetate.
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Less aqueous molecules at the earlier stage and more 
at the later stage can cause a greater increase in the rate of 
swelling in thicker mats than in thinner mats.
In vitro drug release study from 
nanofiber mats
Figure 5 displays the cumulative drug release from PVAc 
nanofibers loaded with different amounts of CipHCl up to 
1920 hours. The results show a relatively quick initial release. 
Moreover, increasing the drug content from 5% to 10% w/w 
approximately doubled the initial drug release.
We deduced that although aqueous 50% acetic acid can 
provide a homogenous solution of PVAc and CipHCl, the 
incompatibility between hydrophobic PVAc and hydrophilic 
CipHCl45 would increase the migration of the drug molecules 
toward the nanofibers surface during the rapid elongation 
and quick solvent evaporation during electrospinning. These 
superficial drug molecules can easily diffuse into the aqueous 
medium and cause an initial quick burst release. As a result, 
by increasing the drug content, a greater portion of the drug 
will be located near the surface; therefore, initial release of 
the drug will be faster.16
After a quick burst release, the profiles of release fol-
lowed a linear fashion with a very slow rate, ie, about 50% 
of the drug was released over 80 days of the experiment. 
This prolonged period of drug release has never been seen 
in nanofibers before.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Figure 5 Effect of drug content on release profiles of CipHCl from PVAc (32% w/v) 
electrospun nanofiber mats vs time (n = 3).
Abbreviations: CipHCl, ciprofloxacin HCl; PVAc, polyvinyl acetate.
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Figure 6 Effect of drug content on release profiles of CipHCl from PVA (5% w/v) 
electrospun nanofiber mats vs time (n = 3).
Abbreviations: CipHCl, ciprofloxacin HCl; PVAc, polyvinyl acetate.
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Figure  7  Effect  of  polymers  blending  on  the  release  profiles  of  CipHCl  from 
medicated electrospun nanofiber mats containing 10% w/w CipHCl vs time (n = 3).
Abbreviations:  CipHCl,  ciprofloxacin  HCl;  PVA,  polyvinyl  alcohol;  PVA/PVAc, 
polyvinyl acetate.
The release profiles of CipHCl from the PVA electrospun 
nanofibers shown in Figure 6 indicate a high initial release 
as well as a rapid release rate in which total release time was 
about 80 hours for both amounts of the drug loaded. It has 
been found that one of the significant factors contributing to 
drug release in controlled release systems is the behavior of 
the matrix loaded with the drug in the release medium. As 
soon as a PVA matrix is exposed to a liquid medium, it begins 
to swell (Figure 4A), its molecular chains are solvated, and 
weight loss occurs (Figure 4B). As a result, the high degree of 
swelling along with the dissolution of the PVA nanofiber mats, 
which is attributed to its poor stability in aqueous mediums, 
causes a quick burst release, as reported previously.8,20,18
According to these profiles, increasing the drug   content 
in PVA nanofiber mats from 5% to 10% w/w lowered initial 
drug release and improved the control of the release profile. 
According to Figure 4A, at the initial experiment stages, 
a higher drug content (10% w/w) in PVA nanofiber mats 
results in a lower degree of swelling. Consequently, the pen-
etration of the receiving liquid phase through PVA nanofibers 
decreases and diffusion of the drug from the nanofibers will 
be retarded. Kumbar and Aminabhavi46 and Sanli et al22 
studied indomethacine release from polyacrylamide grafted 
chitosan microspheres and diclofenac sodium release from 
PVA–sodium alginate beads, respectively. They also observed 
that increasing the drug content slowed drug release.
Figure 7 compares the effect of polymeric matrix on the 
initial drug release and the rate of drug release. While PVAc 
nanofiber mats showed a very slow drug release (regard-
less of the quick initial release), and PVA nanofiber mats 
exhibited a rapid rate of drug release and blend nanofiber 
mats of PVA:PVAc (50:50) a moderate CipHCl release rate 
(Figure 7). In other words, incorporation of hydrophobic 
PVAc into PVA nanofibers decreased the diffusion of release 
medium into nanofiber mats (Figure 4A) and reduced the 
weight loss (Figure 4B). As a result, it could be possible to 
control the rate and the burst release of the drug, in com-
parison with PVA nanofiber mats, to prolong drug release 
to at least 250 hours.
Figure 8 illustrates the effect of the thickness of blend 
nanofiber mats on the release profile if the diameters of 
the nanofibers were the same. Both the initial release and 
the rate of drug release from the blend nanofiber mats of International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
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  Peppas equation,20 zero order, first order, Higuchi, and 
  Hixson–Crowell models.40 The results of regression analysis 
of data by the Peppas equation and the values of exponent 
(n) in that equation are shown in Table 1.
The results indicate the predominance of Fickian diffu-
sion mechanism of release for all formulations, which means 
that the amount of drug loaded, the type of polymer and the 
thickness of nanofiber mats did not influence the drug release 
mechanism.
Generally, drug release from a polymeric matrix is 
described by a Fickian mechanism when drug diffusion is 
the main factor in drug release. Diffusion of the drug from a 
polymeric matrix can occur through two mechanisms: drug 
diffusion out of the matrix and/or drug diffusion because of 
matrix degradation.48
The regression coefficient analysis of release data for 
different kinetic models can be seen in Table 2. This table 
shows that in PVAc nanofibers, the high level of initial 
release (up to 72 hours) is probably related to the diffusion 
of the drug located near the nanofibers surfaces, which 
can be fitted to a Higuchi model. Afterwards, from 72 to 
1920 hours, drug release from PVAc nanofibers can be fitted 
to a Hixson–Crowell model, ie, after 72 hours, the drug was 
released because of the erosion of the PVAc nanofiber mats. 
In fact the release behavior can be described by bimodel 
behavior. Therefore, the erosion mechanism implies dif-
fusion of the drug into the medium.   Degradation does 
not mean complete degradation but involves   degradation 
of nanofibers layer by layer over time, which implies 
erosion.
For Table 2, Higuchi is the best model to fit the drug 
release mechanism from PVA and the blend PVA:PVAc 
(50:50) nanofiber mats, because drug diffusion out of these 
nanofiber mats plays the main role in drug release.
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Figure 8 effect of thickness on the release behavior from medicated electrospun 
nanofiber mats of PVA:PVAc (50:50) containing 10% w/w CipHCl vs time (n = 3).
Abbreviations:  CipHCl,  ciprofloxacin  HCl;  PVA,  polyvinyl  alcohol;  PVA/PVAc, 
polyvinyl acetate.
PVA:PVAc (50:50) significantly decreased as the thickness 
of the mats increased, which was related to the swelling 
behavior of these mats (Figure 4C). Furthermore, the total 
release time was considerably increased, from 72 hours to 
325 hours, by increasing the thickness of the mats from 
100 to 140 µm to 680 to 760 µm, respectively. A possible 
explanation lies in the fact that increasing the thickness of 
nanofiber mats makes the diffusion passage more compact 
for the drug to be released out of the matrix, which reduces 
the amount of drug release.
Based on physical evaluations by touch after submer-
sion, PVAc nanofiber mats were too hard to be applied as a 
wound dressing whereas PVA nanofiber mats and samples 
of PVA:PVAc (50:50) blend nanofiber mats showed very 
good flexibility, and could be bent to cover a wound   surface. 
However, for antibiotic delivery systems, a high initial 
release is necessary to eliminate bacteria before they begin to 
  proliferate.47 Also, a sustained release of antibiotic for about 
1 week is needed for infected wounds to prevent further pro-
liferation of bacteria.5 Blend nanofiber mats of PVA:PVAc 
(50:50) loaded with CipHCl with a thickness of more than 
300 to 360 µm showed a relatively quick initial release as 
well as a sustained release for at least 10 days; moreover, 
these mats were able to swell substantially and were flexible 
and were able to conform to the wound, both of which are 
requirements for wound dressings.
Analysis of drug release kinetics
In order to further assess the mechanism of drug release, 
the  cumulative  release  profiles  were  analyzed  by 
Table  1  Diffusion  constant  (n)  and  regression  coefficient  of 
ciprofloxacin HCl release from PVA, PVAc, and blend nanofiber 
mats calculated by Peppas equation (Mt/M∞ = ktn) (n = 3)
Nanofiber  
type
Thickness  
of mat (μm)
CipHCL  
(% w/w)
R2 ± SD N ± SD
PVA 300–360 5 0.99 ± 0.04 0.15 ± 0.00
10 0.99 ± 0.02 0.27 ± 0.01
5 0.95 ± 0.02 0.15 ± 0.00
PVAc 300–360
100–140
10 0.93 ± 0.01
0.85 ± 0.06
0.083 ± 0.00
0.010 ± 0.01
PVA:PVAc  
(50:50)
300–360 
690–780
10 0.95 ± 0.04 
0.97 ± 0.06
0.18 ± 0.00 
  0.19 ± 0.02
Abbreviations:  CipHCl,  ciprofloxacin  HCl;  PVA,  polyvinyl  alcohol;  PVA/PVAc, 
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Table 2 Regression coefficients of different mathematical models fitted to the release of ciprofloxacin HCl from different nanofibers 
with the thickness of 300 to 360 µm (n = 3)
Nanofibers type CipHCL (% w/w) Zero order First order Higuchi Hixon–Crowell
PVA 5 0.65 ± 0.05 0.79 ± 0.04 0.92 ± 0.06 0.28 ± 0.05
10 0.71 ± 0.01 0.85 ± 0.01 0.94 ± 0.02 0.36 ± 0.04
PVAc before 72 h 5 0.35 ± 0.04 0.41 ± 0.06 0.68 ± 0.02 0.29 ± 0.03
10 0.45 ± 0.06 0.45 ± 0.03 0.78 ± 0.03 0.30 ± 0.02
PVAc after 72 h 5 0.96 ± 0.04 0.93 ± 0.01 0.94 ± 0.03 0.98 ± 0.03
10 0.98 ± 0.05 0.92 ± 0.01 0.95 ± 0.02 0.99 ± 0.06
PVA:PVAc (50:50) 10 0.66 ± 0.06 0.72 ± 0.15 0.90 ± 0.04 0.38 ± 0.09
Abbreviations: CipHCl, ciprofloxacin HCl; PVA, polyvinyl alcohol; PVA/PVAc, polyvinyl acetate.
Conclusion
Continuous uniform nanofibers of PVA, PVAc, and a blend 
of these polymers loaded with CipHCl were successfully 
electrospun. Addition of the drug reduced the size and 
narrowed the distribution of electrospun nanofiber diam-
eters, which could be attributed to the decrease in solu-
tion   viscosity. The amount of drug loaded in nanofibers 
affected the release behavior and the initial drug release 
from PVA and PVAc nanofibers. Regardless of the initial 
rapid release, rate of drug release from PVAc electrospun 
nanofibrous mats was very slow: about 50% of the drug 
was released during 80 days in a linear fashion, whereas 
the PVA nanofiber mats released the drug within 3 days. 
Using the blend nanofiber mats of PVA:PVAc (50:50) 
greatly affected drug release behavior; it reduced the 
amount of the drug released at earlier stages, and sustained 
the drug release profile for longer times compared with 
PVA nanofiber mats. However, blending PVAc with PVA 
solution made blend nanofiber mats more flexible and more 
comfortable for use as a wound dressing because of a very 
significant increase in the degree of swelling comparison 
with PVAc.   Increasing the thickness of the blend nanofiber 
mats controlled both the initial release and the rate of drug 
release, and increased the degree of swelling, making the 
mats suitable for healing deep wounds. All formulations 
showed Fickian drug release kinetics.
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